Esperion Therapeutics, a biotech that Pfizer spent $1.3 billion acquiring in 2003, is free once more. And its founder, Roger Newton, is apparently putting the band back together. Newton, in fact, has just pulled off one of the rarer and most complicated moves in biotechnology -- the...
Pfizer Inc Spinout of Esperion Therapeutics - Founding Team to Focus on HDL Therapies As a Private Entity ANN ARBOR, Mich. & NEW YORK -- Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today...
Byline: Tom Henderson Ann Arbor-based Avalon Investments began raising $100 million and eventually invested in 24 companies. It had some failures, some modest successes and two home runs. They were: Esperion Therapeutics Avalon invested $2.5 million in Ann Arbor-...
Resverlogix Corp. ("Resverlogix") (TSX: RVX) is pleased to announce today that the Board of Directors has appointed Roger Newton, PhD, to the Board effective July 10, 2007. "I am very pleased to be joining the Board of Directors of Resverlogix. It is a very exciting time for the NexVasTM Plaque...
Michigan's venture-capital industry has begun to gain momentum, but success stories have been growing for years. Here are six examples of companies that turned a good idea into venture-capital success: Arbortext: The big payoff Arbortext Inc., a maker of business editing...
Pfizer unsure of local effects of end of drug research A spokesman for Pfizer Inc. said it's unclear how the company's announcement to end research on a potential blockbuster drug would affect Michigan. The company did announce Nov. 28 that it would...
Resverlogix Corp. ("Resverlogix") (TSX: RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action MOA is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in the marketplace regarding cholesterol management drugs, Resverlogix verifies that its lead candidate...
CALGARY, ALBERTA, Dec 5, 2006 CCNMatthews via COMTEX -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action MOA is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in...
Tuesday Nov. 7 GLEQ/Spark Business Accelerator: Entrepreneurs' Roundtable. 6-8 p.m. Ann Arbor IT Zone. Speakers: Christine Gibbons of Sensicore, Michael Long of Velcura, Luke Pinkerton of Polytorx and Maryann Andreach of Esperion. Free. Spark Central, Ann Arbor. Contact: (734) 615-9310 or...
Adam Tomasi, Ph.D Joins as Kauffman Fellow SAN FRANCISCO -- Alta Partners, a life sciences venture capital firm based in San Francisco, today announced that Alison de Bord has been promoted to Director. Alison joins Alta's other six Directors responsible for investing Alta Partners VIII. She currently represents...
A-2 N. Brooks, R. Devalaraja, C. Whitinger, S. Drake. Esperion Therapeutics, Division of Pfizer Global Research and Development, Ann Arbor, MI, Peripheral blood examination from Wistar rats following treatment with agents enhancing cholesterol mobilization revealed large vacuolated mononuelear cells in toxicology studies, the goal of this study was to eharaeterize...
Byline: Tom Henderson So far, it's just a trickle, but national venture-capital firms are starting to discover Michigan. "I look at Michigan as one of the relatively small handful of regions that deserves more attention than the venture-capital world gives it,''...
Biotechnology Timothy Mayleben, COO, Esperion Therapeutics, elected to the board of directors of Aastrom Biosciences Inc., Ann Arbor. Construction Cassandra Newman to director of client marketing, Schonsheck Inc., Wixom, from outside sales manager, Enderle Fastening Systems, Brighton. ...
Wednesday July 27 Michigan Leaders Read: How Esperion Used Good to Great to Drive Their Business Success. Part of the LeadersConnect Breakfast Series. 7:30-9:15 a.m. Speaker: Roger Newton, CEO and founder, Esperion Therapeutics. Ann Arbor IT Zone, 330 E. Liberty St.,...
BALTIMORE -- Alba Therapeutics Corporation today announced the first appointments to its Corporate Advisory Board and also announced the appointment of Chris Jeffers, Ph.D., J.D. as General Counsel and Vice President Intellectual Property. Alba's first appointees to its Corporate Advisory Board are Tim Mayleben, MBA and Roger Newton, PhD. Dr....
NEW YORK -- Pfizer Inc.'s profit dropped 50 percent in the first quarter because of charges associated with acquisitions as well as a tough comparison with results a year ago that were fattened by more than $2 billion in proceeds from selling consumer lines. But the results...
Business Editors/Health/Medical Writers BIOMED EXPO 2004 ANN ARBOR, Mich.--BUSINESS WIRE--April 20, 2004 Michigan Governor Jennifer Granholm will participate in the closing reception at BioMed Expo 2004 to present an honorary award to Esperion Therapeutics, a division of Pfizer Global Research and Development. The event...
CALGARY, ALBERTA, Mar 25, 2004 CCNMatthews via COMTEX Resverlogix Corp. (TSX-V:RVX) today announced the appointment of Jan O. Johansson, M.D., Ph.D., as Senior Vice President of Clinical Affairs. "I'm fascinated by the opportunities provided by Resverlogix technologies in the...
PFIZER'S PLAN to buy Esperion Therapeutics for $1.3 billion is a move by the drug maker to solidify its dominance of the cholesterol drug market, Standard & Poor's wrote in its weekly financial newsletter The Outlook. Esperion's gold nugget is its drug ETC-216. Studies have shown that ETC-216 significantly...
Articles 2004-02-01
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
